(NASDAQ: GRFS) Grifols Sa's forecast annual revenue growth rate of 8.48% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.56%.
Grifols Sa's revenue in 2025 is $8,013,757,777.On average, 1 Wall Street analysts forecast GRFS's revenue for 2025 to be $6,020,505,796,411, with the lowest GRFS revenue forecast at $6,020,505,796,411, and the highest GRFS revenue forecast at $6,020,505,796,411. On average, 1 Wall Street analysts forecast GRFS's revenue for 2026 to be $6,534,776,240,948, with the lowest GRFS revenue forecast at $6,534,776,240,948, and the highest GRFS revenue forecast at $6,534,776,240,948.
In 2027, GRFS is forecast to generate $6,895,488,172,332 in revenue, with the lowest revenue forecast at $6,895,488,172,332 and the highest revenue forecast at $6,895,488,172,332.